Walmart has resolved a U.S. government lawsuit claiming its pharmacies mishandled opioid prescriptions. Federal prosecutors and the company announced the agreement on August 28 without revealing financial details.
The 2020 lawsuit alleged Walmart broke controlled substance laws through its pharmacy network starting in 2013. Authorities had warned of potential multibillion-dollar fines. This settlement concludes federal claims after Walmart's earlier $3.1 billion payment to address lawsuits by states and municipalities.
"The department is pleased to have reached a settlement with Walmart resolving allegations that its pharmacies failed to comply with their obligations under the Controlled Substances Act in dispensing opioids and other controlled substances," a Justice Department spokesperson said.
Walmart stated: "We are pleased to resolve this matter and will continue supporting the exceptional work our pharmacists do every day to provide outstanding patient care." Court documents show both parties filed dismissal paperwork in Delaware the prior day.
This case stood among the Justice Department's largest opioid enforcement actions against individual corporations. Other major targets were Purdue Pharma, admitting criminal wrongdoing in 2020 over OxyContin marketing, and pharmaceutical distributor Cencora (previously AmerisourceBergen).
The federal government's case against Walmart focused on pharmacies' legal responsibility to monitor prescription patterns under the Controlled Substances Act. Pharmacies must maintain safeguards against suspicious orders, including verifying prescriptions with doctors when red flags appear. Walmart's extensive pharmacy network, with thousands of locations nationwide, placed it under particular scrutiny as opioid overdose deaths surged in the 2010s.
Even amid market uncertainty, safeguard your future with the free Always Be Buying E-Book for disciplined investing
Judge Colm Connolly streamlined the case in early 2024 by dismissing certain claims but permitting others about prescription verification to advance. The new agreement closes all outstanding allegations.
Pharmacies play a key role in opioid oversight under federal law, required to flag suspicious prescribing patterns. Walmart operates one of the nation's largest pharmacy networks, filling hundreds of millions of prescriptions annually. Government data shows U.S. opioid overdose deaths totaled over 905,000 from 1999-2025, with fatalities peaking in 2022 before trending downward.
Investors reacted favorably to the legal resolution, with Walmart stock gaining 0.5%. The company asserts its pharmacists adhered to protocols while recognizing systemic challenges in opioid dispensing.
The settlement removes significant legal uncertainty for Walmart's pharmacy division. Having now addressed both federal and state opioid litigation, the retailer can concentrate on adapting to changing regulations while growing its healthcare services.
For shareholders, resolving this high-profile case eliminates a persistent risk factor. Walmart's pharmacies remain critical to its broader health strategy, which includes expanding clinical services and telehealth offerings alongside traditional prescription filling.